New Spotlight on CDER Science on Laboratory and Clinical Studies to Investigate Reports of NDMA Production from Ingested Ranitidine Products - Drug Information Update

If your email program has trouble displaying this email, view it as a web page. Ensuring the Rigor of Regulatory Science: CDER Conducts Laboratory and Clinical Studies to Investigate Reports of NDMA Production from Ingested Ranitidine Products CDER's commitment to regulatory science involves the development of sound scientific methods and the performance of laboratory and clinical studies when needed to address reports of drug product contamination. Laboratory and clinical investigations, currently appearing in JAMA, showcase the mobilization of CDER research capabilities in the interest of protecting public health. Learn More This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA